Geron (NASDAQ:GERN) Posts Quarterly Earnings Results, Hits Estimates

Geron (NASDAQ:GERN) issued its earnings results on Wednesday. The biopharmaceutical company reported ($0.04) EPS for the quarter, hitting analysts’ consensus estimates of ($0.04), Zacks reports. Geron had a negative net margin of 682.48% and a negative return on equity of 67.53%. The company had revenue of $47.54 million for the quarter, compared to analysts’ expectations of $45.29 million.

Geron Stock Performance

NASDAQ:GERN opened at $1.64 on Thursday. The stock has a 50-day simple moving average of $3.00 and a two-hundred day simple moving average of $3.81. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.74 and a current ratio of 2.89. Geron has a 52-week low of $1.46 and a 52-week high of $5.34. The firm has a market capitalization of $988.36 million, a PE ratio of -5.11 and a beta of 0.53.

Wall Street Analyst Weigh In

GERN has been the topic of several analyst reports. Needham & Company LLC decreased their target price on shares of Geron from $7.00 to $5.00 and set a “buy” rating on the stock in a research note on Thursday. Barclays restated an “overweight” rating and issued a $4.00 price target (down previously from $9.00) on shares of Geron in a research note on Thursday. HC Wainwright cut Geron from a “buy” rating to a “neutral” rating in a research note on Wednesday. Finally, B. Riley downgraded shares of Geron from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $3.50 to $2.00 in a research note on Thursday. One investment analyst has rated the stock with a sell rating, three have given a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $6.14.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.